Despite the recent evidence of the existence of myelodysplastic syndrome (MDS) stem cells
in 5q-MDS patients, it is unclear whether haematopoietic stem cells (HSCs) could also be …

Mutations in the RNA splicing gene SF3B1 are found in> 80% of patients with
myelodysplastic syndrome with ring sideroblasts (MDS-RS). We investigated the origin of …

Abstract SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS),
but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a …

The 2016 revision of the World Health Organization classification of tumors of hematopoietic
and lymphoid tissues is characterized by a closer integration of morphology and molecular …

Background The presence of somatic mutations in splicing factor 3b subunit 1 (SF3B1) in
patients with Myelodysplastic syndromes with ring sideroblasts (MDS-RS) highlights the …

Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS)
characterized by isolated erythroid dysplasia and 15% or more bone marrow ring …

Background Recurrent somatic mutations in SF3B1 have been identified in patients with
myelodysplastic syndromes (MDS) and are associated with ring sideroblasts (RS) and …

SF3B1 mutations were recently reported in myelodysplastic syndromes (MDSs), especially
in the presence of ring sideroblasts (RSs). We sought to define the interaction between …

The 2016 iteration of the World Health Organization (WHO) classification of myeloid
neoplasms includes myelodysplastic syndrome with ring sideroblasts (MDSRS) as a unique …

According to the recently updated tumor classification by the World Health Organization,
myelodysplastic syndrome (MDS) constitutes a heterogeneous group of blood disorders …